Literature DB >> 29876615

[Oligometastases of neuroendocrine tumors-extent of surgery].

F Bösch1, J Werner2, M K Angele2, M O Guba2.   

Abstract

Neuroendocrine tumors (NETs) are rare neoplasms, which represent complex challenges in diagnosis and treatment. Even in the metastatic stage there are important differences in the type of tumor in comparison to gastrointestinal and pancreatic adenocarcinomas. Therefore, the disease courses are substantially different depending on the grade of differentiation. Even in the metastatic stage the 5‑year survival rates of G1 tumors is up to 83%. Approximately 20% of small intestine NETs additionally show hormone activity, which can compromise survival and the quality of life. For individual treatment decisions the special tumor biology of these tumors must be taken into consideration more so than for other tumor entities. Surgery always becomes important for these tumors when a R0 resection appears possible. Oligometastasis of the liver and the lymph drainage system can be meaningfully approached by surgical treatment. In selected patients with an isolated liver involvement, a liver transplantation can be considered; however, even tumor debulking can lead to improvement in the quality of life and survival, especially for hormone active tumors with a carcinoid syndrome which cannot be conservatively controlled. The aim of this review is to present the value of surgical treatment options in the case of (oligo)metastasized NETs.

Entities:  

Keywords:  Liver metastases; Liver transplantation; Multimodal therapy; Peritoneal carcinomatosis; Preoperative management

Mesh:

Year:  2018        PMID: 29876615     DOI: 10.1007/s00104-018-0644-z

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  29 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

Authors:  M Pavel; D O'Toole; F Costa; J Capdevila; D Gross; R Kianmanesh; E Krenning; U Knigge; R Salazar; U-F Pape; K Öberg
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

3.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

Authors:  Vincenzo Mazzaferro; Andrea Pulvirenti; Jorgelina Coppa
Journal:  J Hepatol       Date:  2007-07-26       Impact factor: 25.083

4.  Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach.

Authors:  Akshat Saxena; Terence C Chua; Anik Sarkar; Francis Chu; Winston Liauw; Jing Zhao; David L Morris
Journal:  Surgery       Date:  2010-08-02       Impact factor: 3.982

5.  Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.

Authors:  Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2010-06-29       Impact factor: 5.344

6.  Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.

Authors:  Henning Jann; Stephanie Roll; Anne Couvelard; Olivia Hentic; Marianne Pavel; Jacqueline Müller-Nordhorn; Martin Koch; Christoph Röcken; Guido Rindi; Philippe Ruszniewski; Bertram Wiedenmann; Ulrich-Frank Pape
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

8.  The small remnant liver after major liver resection: how common and how relevant?

Authors:  Cengizhan Yigitler; Olivier Farges; Reza Kianmanesh; Jean-Marc Regimbeau; Eddie K Abdalla; Jacques Belghiti
Journal:  Liver Transpl       Date:  2003-09       Impact factor: 5.799

9.  Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases).

Authors:  Dominique Elias; Anaelle David; Isabelle Sourrouille; Charles Honoré; Diane Goéré; Frédéric Dumont; Annabelle Stoclin; Eric Baudin
Journal:  Surgery       Date:  2013-09-29       Impact factor: 3.982

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  1 in total

1.  Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection.

Authors:  Florian Bösch; Harun Ilhan; Vanessa Pfahler; Michael Thomas; Thomas Knösel; Valentin Eibl; Sebastian Pratschke; Peter Bartenstein; Max Seidensticker; Christoph J Auernhammer; Christine Spitzweg; Markus O Guba; Jens Werner; Martin K Angele
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.